Revolution Medicines delivered what oncologists described as “landscape-changing” data for daraxonrasib at ASCO, extending survival in second-line metastatic pancreatic cancer with RAS-pathway–driven tumors. In the Phase 3 trial, daraxonrasib nearly doubled median survival versus standard chemotherapy, with fuller ASCO details indicating a median 13.2-month survival across the full study population. The study focused on patients whose disease progressed after prior treatment and whose tumors were driven by a RAS G12 mutation, while also evaluating outcomes in broader groups. Across all daraxonrasib-treated recipients, investigators reported median survival of 13.2 months versus 6.6 months with chemotherapy in the RAS G12 subgroup and similar outcomes across the all-comer population. Revolution also highlighted durable disease control: median progression-free timeframes roughly doubled compared with chemotherapy, and early safety signals were framed as consistent with an “expected safety profile.” Multiple investigators pointed to rapid patient-reported improvements, including pain and tumor marker responses, following initiation. Separate ASCO coverage reinforced the intensity of the immunotherapy race in China, where Akeso and Summit’s ivonescimab showed a 34% reduction in risk of death in previously untreated Chinese patients with squamous non-small cell lung cancer, published alongside the clinical readout in The Lancet.